IP Library › Granted Patent US 10,780,046
Granted Patent B2
US 10,780,046 · App. 16/386,983 · Granted Sep 22, 2020

Pharmaceutical compositions comprising silica microspheres

Inventors: Marina Shevachman (Beer-Sheva, IL); Amira Ze'Evi (Omer, IL); Eilon Asculai (Lehavim, IL); Batella Binyaminovich (Beer-Sheva, IL); Nir Avram (Meitar, IL); Chaim Aschkenasy (Yeruham, IL)
Assignee: SOL-GEL TECHNOLOGIES LTD.
A61K9/0034A61K9/0014A61K9/06A61K9/143A61K9/1611A61K31/05A61K31/192A61K31/203A61K31/327A61K31/4164A61K31/4174A61K31/4436A61K31/565A61K31/7056A61K45/06A61K47/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,780,046
App. No.
16/386,983
Granted
Sep 22, 2020
Kind
B2
Abstract

Topical vaginal compositions are disclosed herein which include silica microspheres and an active ingredient in the amount of 0.001 to 15.0% w/w selected from estradiol, metronidazole, clindamycin, butoconazole, and combinations thereof. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation.

Claims (12)

1. A sustained release composition for topical application of pharmaceuticals comprising:

3% w/w of benzoyl peroxide and 0.1% w/w tretinoin as the active ingredients, and

silica microspheres, formed prior to contact with the active ingredients, impregnated with the active ingredients.

2. The sustained release composition of claim 1 , wherein some of the active ingredients are free in the composition, and the active ingredients impregnated in the silica microspheres provides sustained release of the active ingredients.

3. The sustained release composition of claim 1 , wherein the composition is formulated as a foam.

4. The sustained release composition of claim 1 , wherein said sustained release composition is formulated in a semisolid form.

5. The sustained release composition of claim 4 , wherein the semisolid form is a gel, a cream, a paste, a lotion, an ointment, a shampoo, a semisolid powder or a suspension.

6. The sustained release composition of claim 1 , wherein the silica microspheres have a mean microsphere size in the range of 0.5 micron to 40 microns.

7. The sustained release composition of claim 1 , wherein the silica microspheres have a mean microsphere size in the range of 1 micron to 20 microns.

8. The sustained release composition of claim 1 further comprising one or more of a solvent, an antioxidant, an antimicrobial preservative, an emulsifier, and water.

9. The sustained release composition of claim 8 , wherein the solvent is selected from the group consisting of isopropanol, oleic acid, glycerol monooleate, oleyl alcohol, propylene glycol, isopropyl myristate, and combinations thereof.

10. The sustained release composition of claim 1 , wherein the composition may be used to treat skin disorders and diseases, including atopic dermatitis, psoriasis, rosacea, actinic keratosis, acne, skin pigmentation and other types of skin inflammations or viral, fungal or bacterial skin infections.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2020
From: SHEVACHMAN, MARINA; ZE' EVI, AMIRA; ASCULAI, EILON; BINYAMINOVICH, BATELLA; AVRAM, NIR; ASCHKENASY, CHAIM
To: PERRIGO ISRAEL PHARMACEUTICALS LTD.
Reel/Frame 051862/0058 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2020
From: PERRIGO ISRAEL PHARMACEUTICALS LTD.
To: SOL-GEL TECHNOLOGIES LTD.
Reel/Frame 051862/0409 →
Continuity (6)
Continuation 15272555 · Sep 22, 2016
Continuation In Part 14551155 · Nov 24, 2014
Continuation 11783895 · Apr 12, 2007
Provisional Application 60791902 · Apr 14, 2006
Provisional Application 60817247 · Jun 29, 2006
Related Publication 20190240149A1 · Aug 8, 2019
Cited By (3)
US 12,201,956 US 12,295,935 US 12,661,407